Madrigal Pharmaceuticals, Inc., planned to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on January 31, 2022. Madrigal's lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-ß selective agonist that is currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
285.7 USD | +3.74% |
|
+6.67% | +23.46% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.46% | 6.09B | |
+16.13% | 122B | |
+19.65% | 113B | |
+21.95% | 26.49B | |
-23.84% | 19.4B | |
-17.47% | 16.24B | |
-45.95% | 15.15B | |
-19.28% | 15.4B | |
+63.81% | 14.93B | |
+1.94% | 13.52B |
- Stock Market
- Equities
- MDGL Stock
- News Madrigal Pharmaceuticals, Inc.
- Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom